20 to 40 percent of the patients with multiple myeloma -- a type of leukemia -- have a defect in the ribosome, the protein factory of the cell. These patients have a poorer prognosis than patients with intact ribosomes. At the same time, they respond better to a drug that already exists, report investigators.
20 to 40 percent of the patients with multiple myeloma -- a type of leukemia -- have a defect in the ribosome, the protein factory of the cell. These patients have a poorer prognosis than patients with intact ribosomes. At the same time, they respond better to a drug that already exists, report investigators.
Share this Article
Recommended